鉅子生物(02367.HK)：2022年經調整淨利潤10.56億元 同比增長24.1%
格隆匯3月27日丨鉅子生物(02367.HK)發佈公吿，截至2022年12月31日止年度，收入為人民幣23.64億元，同比增長52.3%；毛利人民幣19.95億元，同比增長47.3%；歸屬於母公司持有者盈利人民幣10.02億元，同比增長21.0%；年內經調整淨利潤(非《國際財務報吿準則》衡量指標)人民幣10.56億元，同比增長24.1%；每股基本盈利人民幣0.99元。
持續深耕合成生物學平台建設，提升研發實力。強大的科研實力和持續的研發投入是集團穩健發展並保持行業領先地位的基礎。於2022年集團加強了基礎研究投入，強化在合成生物學領域的綜合技術實力，開發儲備新型的重組膠原蛋白、稀有人蔘皂苷和其他生物活性成分，研究將其應用於功效性護膚品、醫用敷料、肌膚煥活產品及保健食品等領域。2022年公司研發支出人民幣4400萬元，同比增長76.5%；研發支出佔收入比例1.9%，同比提升0.3%。截止2022年末，公司已授權及申請中專利80項，其中2022年新增27項；在研項目127項，研發項目均進展順利。依託強大的研發實力，截止2022年末公司擁有121項SKU的豐富產品組合。
持續完善多元化品牌和產品佈局。集團圍繞重組膠原蛋白、稀有人蔘皂苷等生物活性成分，以科技美學為主線，堅持以“真誠、善意、極致、創新”的產品開發理念鍛造強勁產品力，從功效和類型兩方面擴充產品組合，快速響應不斷變化的行業趨勢，滿足多元化的市場需求。目前集團的產品類型包括功效性護膚品、醫用敷料和保健食品等，截至2022年12月31日，集團擁有8個主要品牌，共121項SKU。
持續提升品牌學術影響力，打造品牌科技美學價值。集團採用科學傳播的方式鞏固品牌的科技美學價值主張。集團通過參與行業標準制定、專家共識發佈、學術交流等活動，持續提升公司旗下品牌知名度及學術影響力。2022年9月，由公司攜手其他皮膚科行業專家共同編纂的重組膠原蛋白行業首個專家共識《重組膠原蛋白在皮膚病與皮膚護理中的應用》正式發佈。這部專着引領行業科學化規範化的發展，為皮膚科醫師的臨牀治療提供了專業的參考，並給消費者提供了科學的肌膚護理指導。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
